Cardiol Therapeutics (TSX: CRDL) is a leader in the research and commercial development of pharmaceutical cannabidiol products and targeted therapies for heart failure and cancer.
Agreements with Noramco and Dalton Pharma provide access to cannabinoid pharmaceuticals.
Nanotechnology research aims to enhance the delivery of cannabinoids for heart failure.
Cannabinoid drug candidates for the treatment of heart failure and Glioblastoma Multiforme.
Team is experienced in the research and commercialization of novel therapeutics.
Cardiol aims to commercialize its pharmaceutical cannabidiol during 2019 and set a new standard for purity and consistency.
The company also aims to advance its lead product candidate from the CTX series nano formulations for heart failure and its GBM product into clinical development during 2019.
These could become catalysts for the stock this year.
Copyright © 2018 All Rights Reserved.